Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $2.8 million.

  • Beam Therapeutics' Treasury Shares fell 1342.77% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 1342.77%. This contributed to the annual value of $2.6 million for FY2024, which is 1196.72% down from last year.
  • As of Q3 2025, Beam Therapeutics' Treasury Shares stood at $2.8 million, which was down 1342.77% from $2.9 million recorded in Q2 2025.
  • Beam Therapeutics' Treasury Shares' 5-year high stood at $3.4 million during Q1 2024, with a 5-year trough of $1.1 million in Q4 2021.
  • For the 5-year period, Beam Therapeutics' Treasury Shares averaged around $2.2 million, with its median value being $2.2 million (2023).
  • As far as peak fluctuations go, Beam Therapeutics' Treasury Shares plummeted by 3879.41% in 2021, and later soared by 7291.58% in 2023.
  • Over the past 5 years, Beam Therapeutics' Treasury Shares (Quarter) stood at $1.1 million in 2021, then soared by 50.31% to $1.7 million in 2022, then surged by 72.92% to $2.9 million in 2023, then decreased by 11.97% to $2.6 million in 2024, then rose by 7.96% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $2.9 million for Q2 2025, and $3.1 million during Q1 2025.